NKIRA™ is KweHealth’s next-generation immuno-oncology platform, built on the extraordinary power of Natural Killer (NK) cells—the innate immune system’s first responders against cancer and infection. Unlike conventional therapies, NKIRA™ leverages NK cells’ unique ability to recognize and destroy malignant cells without prior sensitization, providing a broad-spectrum, rapid-response therapeutic advantage.

By uniting immunotherapy and regenerative medicine, NKIRA™ goes beyond simply eliminating tumors. It is designed to restore health, support tissue repair, and improve patient resilience, offering a patient-centered approach that reduces toxicity compared to traditional chemotherapy and radiation.

At its core, NKIRA™ is about adaptability. Solid tumors create hostile microenvironments—marked by hypoxia, metabolic stress, and immunosuppressive signals—that cripple conventional immune responses. NKIRA™ overcomes this challenge by priming and engineering NK cells with enhanced metabolic flexibility and durability, ensuring sustained cytotoxicity even in the most suppressive conditions.

The result is a transformative therapeutic platform: adaptable, regenerative, and uncompromising in its mission to provide robust, long-term efficacy against some of the most refractory solid tumors, including glioblastoma, head and neck cancers, and pancreatic cancer.

NKIRA™ redefines the future of cancer care—where immunity, regeneration, and adaptability converge to create powerful, lasting outcomes for patients.